The 20 Best T-Cell Lymphoma Doctors in Maryland, US

Dr. Sima Rozati is an Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine. She specializes in medical dermatology, cutaneous lymphoma, and supportive oncodermatology. She received her medical degree from the Shahid Beheshti University of Medical Sciences in Tehran. After completing her internal medicine residency at the Cleveland Clinic, she completed a research fellowship and PhD in cutaneous lymphoma at the University Hospital of Zürich in Switzerland. She returned to the U.S. where she completed cutaneous lymphoma fellowship, under the mentorship of Dr. Youn Kim, followed by dermatology residency at Stanford University School of Medicine in California. In a multidisciplinary environment, Dr. Rozati aims to provide excellent care to patients with cutaneous lymphoma and cancer whom are experiencing cutaneous adverse events from targeted therapies, immune- and chemotherapies. Dr. Rozati’s research interest focuses on cutaneous lymphoma, understanding the biology of this heterogeneous group of malignancies by analyzing the mutational and epigenetic landscape. Her translational research efforts is directed to investigate novel targeted and immunotherapeutic for cutaneous T cell lymphoma. She is a member of different professional organizations, including the American Academy of Dermatology and Woman’s dermatologic Society. Dr. Rozati is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, T-Cell Lymphoma, and Sezary Syndrome.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

"Daniel J. Lewis, M.D. is a dual fellowship-trained Mohs and reconstructive surgeon and Assistant Professor of Dermatology at Johns Hopkins University School of Medicine. He leads the Mohs surgery unit at the Johns Hopkins Outpatient Center (JHOC), the hospital's flagship facility in downtown Baltimore. He is also heavily involved in education as the director of the JHOC resident surgery clinic and as core faculty for the Micrographic Surgery and Dermatologic Oncology fellowship. Dr. Lewis earned a B.A. in Biology from the University of Pennsylvania, earned his M.D. at Baylor College of Medicine while completing a research fellowship at The University of Texas MD Anderson Cancer Center, and completed his internship at Memorial Sloan Kettering Cancer Center. He then returned to Penn for dermatology residency, serving as chief resident at the country's No. 1-ranked dermatology program by Doximity. At Penn, he pursued further specialization with two year-long post-doctoral fellowships in cutaneous oncology and Mohs micrographic surgery. During his Mohs fellowship at Penn, Dr. Lewis worked at the largest academic Mohs surgery center in the country alongside leaders in the field and pioneers in the use of Mohs surgery with immunohistochemistry, complex reconstruction, high-risk tumors, and tumors on specialty sites. Dr. Lewis has authored over 90 peer-reviewed manuscripts in high-impact journals such as Journal of the American Academy of Dermatology, JAMA Dermatology, and Journal of Investigative Dermatology. He has also served on the Editorial Board of the International Journal of Dermatology and has authored multiple textbook chapters as well as two editions of the book Practical Ways to Improve Patient Adherence, named the winner of the 2022 ""Best Overall"" Dermie Award by Dermasphere. Dr. Lewis is an aspiring leader in cutaneous oncology and was named Post-Doctoral Trainee of the Year in 2022 by ADEN, winner of the 2022 ASDS Young Investigators Writing Competition, and a Rising Scholar by the Dermatology Foundation in 2023. He is a member of the Alpha Omega Alpha Honor Medical Society. He is passionate about Mohs micrographic surgery and has clinical interests in advanced facial reconstruction, Mohs surgery with immunohistochemistry, facial anatomy, Merkel cell carcinoma, melanoma, and patient adherence.". Dr. Lewis is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, and Sezary Syndrome.

Dr. Ronald Sweren is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous lymphoma/mycosis fungoides, phototherapy/ photopheresis and melanoma. Dr. Sweren also serves as director of the Phototherapy/Photopheresis Program in the Department of Dermatology. Dr. Sweren earned his M.D. from the University of Maryland School of Medicine. He completed his residency in dermatology at University of Maryland Medical Center and in pediatrics at Sinai Hospital of Baltimore. Dr. Sweren is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Melanoma, and T-Cell Lymphoma.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS).

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as an Advanced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Djordje Atanackovic is a Hematologist in Baltimore, Maryland. Dr. Atanackovic is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard Piekarz is an Oncologist in Bethesda, Maryland. Dr. Piekarz is rated as a Distinguished provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, and Non-Hodgkin Lymphoma.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma.

Dr. Jaroslaw Jedrych is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatopathology and anatomic pathology. Dr. Jedrych received his M.D. from the Warsaw Medical University. He completed his residency in anatomic pathology at Yale School of Medicine, where he served as chief resident. He then completed his fellowship in oncologic pathology at Memorial Sloan Kettering Cancer Center, where he served as chief fellow, and a dermatopathology fellowship at University of Pittsburgh Medical Center. Dr. Jedrych is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Epidermodysplasia Verruciformis, Trichoepithelioma, Warts, and Grover's Disease.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, and Acute Myeloid Leukemia (AML).

Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. Dr. Ambinder is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Blanche Mavromatis, MD, specializes in hematology oncology and is board certified in internal medicine by the American Board of Internal Medicine. Dr. Mavromatis completed her fellowship at Georgetown University Hospital, residency at Georgetown University Medical Center and medical degree from Thomas Jefferson University Medical College. Dr. Mavromatis is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.

Dr. Lilja Bjork Solnes is an Assistant Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her areas of clinical expertise include diagnostic radiology, oncology, and nuclear medicine. Dr. Solnes serves as the director of Nuclear Medicine and Molecular Imaging as well as the director of Radiotheranostics at the Johns Hopkins School of Medicine. Dr. Solnes received her M.B.A. and M.D. degrees from Columbia University College of Physicians and Surgeons. She completed her radiology residency at Columbia University Medical Center and performed fellowships in Radiology and Neuroradiology at Columbia University. She also completed fellowships from Ohio State University Wexner Medical Center in Neuroradiology and Cornell University Medical Center in Radiology. Dr. Solnes is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. Her top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Lymphofollicular Hyperplasia, and Renal Cell Carcinoma (RCC).

Dr. Harry Quon is an associate professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also holds appointments in oncology and in otolaryngology - head and neck surgery. His area of clinical expertise is radiation treatment for head and neck cancers. He serves as the co-director of the Johns Hopkins Head and Neck Cancer Multidisciplinary Clinic. Dr. Quon received his M.D. from the University of Toronto Institute of Medical Science. He completed his residency at the Princess Margaret Hospital in Ontario and performed a fellowship in radiation oncology at the Princess Margaret Hospital and the Beth Israel Medical Center. Make A Gift. Dr. Quon is rated as an Experienced provider by MediFind in the treatment of T-Cell Lymphoma. His top areas of expertise are Laryngeal Cancer, Throat Cancer, Dry Mouth, Gastrostomy, and Prostatectomy.